Siamak MahmoudianDehkordi

The paper uses whole-body metabolic models to link gut microbiota to metabolic changes in Alzheimer's disease, identifying key microbial drivers and metabolites involved.

This study examines how APOE genotypes affect brain metabolome changes with aging in mice, finding that APOE2 genotype is associated with better mitochondrial function and BCAA utilization.

The paper presents a multi-organ metabolomics atlas in AD mouse models, identifying dysregulated metabolites and microbiome associations linked to oxidative stress and cognitive impairment.

This study links medication use to distinct gut microbial features in anxiety and depression, showing antidepressants have a larger effect on microbiota than diagnoses.

The paper examines the association between bile acid levels and functional connectivity of the executive control and default mode networks in patients with major depression.

This study shows that α-synuclein overexpression and the microbiome alter the gut and brain metabolome in mice, with TMAO levels correlating across tissues and linking to PD-like outcomes.

This study identifies associations between bile acid profiles and symptoms of depression and anxiety in MDD patients, finding higher anxiety correlates and treatment failure predictors.

The paper uses targeted metabolomics to analyze changes in acylcarnitines, amines, and lipids in response to citalopram/escitalopram treatment in MDD patients, identifying metabolic correlates of treatment response.

The paper identifies serum metabolites associated with brain amyloid-beta deposition, cognitive dysfunction, and progression to Alzheimer's disease.

The paper investigates sex and APOE ε4 genotype effects on metabolic alterations in Alzheimer’s disease using stratified analysis of serum metabolites.

This study identifies metabolites and pathways in serum and brain tissue associated with cognitive impairment and develops models to predict antecedent cognitive decline in older adults.

The paper identifies differences in bile acid pathways for cholesterol clearance in Alzheimer’s disease by analyzing transcriptomes and metabolomics data from brain samples.

This study identifies metabolomic clusters associated with depressive symptom change and treatment response to CBT in MDD patients.

The paper identifies altered bile acid profiles in Alzheimer's disease, linking them to cognitive impairment and genetic variants through a large study.

The paper identifies associations between serum bile acid metabolites and AD biomarkers in the A/T/N framework, suggesting a potential role for bile acid pathways in AD pathophysiology.